Table 2 Predictive utility of exosomes in lung cancer

Mouse syngeneic tumor model

miR-210-3p, miR-193a-3p, and miR-5100

miR-193a-3p alone can differentiate cancer patients from non-cancerous controls, but the combination of the three gives better diagnostic accuracy

[86]

Primary SCLC tissues and NSCLC tissues

FLI1 exonic circular RNAs

Serum exosomal FECR1 is associated with poor survival and clinical response to chemotherapy

[104]

Human NSCLC tissue

miR‐18a, miR‐20a, miR‐92a, miR‐210, and miR‐126

Prognostic biomarkers in patients with NSCLC—poor prognosis

[109]

NSCLC patients

eIF4E

Independent prognostic factor for shorter overall survival and progression-free survival

[111]

Lung cancer patients’ serum

miR-574-5p, 328-3p and miR-423-3p

Deferential in lung cancer patients with bone metastasis

[78]

NSCLC patients

miR-330-3p

Biomarker for identifying NSCLC with metastatic potential, especially brain metastasis

[80]

Serum of NSCLC patients and lung squamous cell carcinoma of patients

miR-15a-5p, miR-320a, miR-25-3p, miR-192-5p, let-7d-5p, let-7e-5p, miR-148a-3p, miR-92a-3p, miR-375 and miR-10b-5p

Deferential in lung cancer patients and correlates with cancer stage

[99]

NSCLC cells

miR-34c-3p

Diagnostic and prognostic marker for NSCLC with low levels indicating tumor invasion and migration

[116]

Serum of lung cancer patients

miR-106b

Promising diagnostic biomarker and drug target for patients with lung cancer

[100]

Serum of lung cancer patients

CD317 and EGFR

Diagnostic biomarker of NSCLC

[101]

Urine and lung tissue of NSCLC patients

LRG1

Diagnostic biomarker of NSCLC

[102]

Plasma of lung cancer patients

CD151, CD171, and tetraspanin 8

Diagnostic biomarker of lung cancer

[103]